Max Robotics — Global Service Robot Directory + US Certification

About

Chengcai Liang is a leading figure in the surgical treatment of gastric cancer, with a focused expertise in minimally invasive techniques. His major contributions lie in advancing the field of robotic gastrectomy (RG), where he has systematically compared its efficacy against the established laparoscopic gastrectomy (LG). Through large-scale, multicenter cohort studies, Liang has provided critical evidence on both short-term and long-term oncological outcomes. His landmark 2021 study, with 94 citations, demonstrated the safety and feasibility of RG on a broad scale, while his 2024 follow-up, already garnering 14 citations, solidifies these findings by confirming comparable long-term survival and recurrence rates. Beyond comparative effectiveness, Liang has also pioneered the technical refinement of these procedures, as seen in his detailed report on totally robotic total gastrectomy using the da Vinci Xi platform. His work is instrumental in defining the modern surgical standard for gastric cancer, offering patients a path to recovery with less invasive approaches. Liang’s research is a cornerstone for any surgeon or researcher exploring the intersection of oncology and advanced surgical robotics.